HR070803 + oxaliplatin + 5-fluorouracil + calcium folinate

This is a **four-drug combination regimen** comprised of **HR070803 (liposomal irinotecan hydrochloride)**, **oxaliplatin**, **5-fluorouracil**, and **calcium folinate (also called leucovorin)**. - **HR070803** is a novel nanoliposomal formulation of irinotecan designed for prolonged blood circulation and improved tumor penetration, with favorable antitumor efficacy and toxicity profiles compared to conventional irinotecan[1][3][5]. - **5-fluorouracil** is a pyrimidine analog that inhibits thymidylate synthase, blocking DNA synthesis in rapidly proliferating tumor cells[2][6][8]. - **Oxaliplatin** is a platinum-based chemotherapeutic that causes DNA crosslinking and apoptosis[2][4][6][8]. - **Calcium folinate (leucovorin)** stabilizes the binding of 5-fluorouracil to thymidylate synthase, enhancing its cytotoxicity[6][8]. This regimen has shown **improved efficacy and manageable safety profiles** in clinical trials for advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer, especially in patients who have failed prior lines of therapy[1][3][5][6][8]. The combination leverages mechanisms of **DNA damage**, **inhibition of DNA synthesis**, and **potentiation of cytotoxicity**. HR070803 is developed by Hengrui and is being investigated in phase 1b and phase 3 trials, mainly in Asia[1][3][5].

Other names

liposomal irinotecan + oxaliplatin + 5-fluorouracil + leucovorin